Blog
RSS FeedPosted by Michael Wonder on 08 Mar 2023
The unique device identifier: a unique opportunity
7 March 2023 - A unique device identifier is an individualised alphanumeric signature associated with a single medical device. Since 2013, ...
Posted by Michael Wonder on 05 Oct 2021
FDA’s naming rule for biosimilars has undermined Congress and health care
4 October 2021 - I recently tried to order white blood cell growth factor (pegfilgrastim) biosimilar for one of my ...
Posted by Michael Wonder on 24 Jul 2019
FDA seeks input on biomarker, endpoint glossary
24 July 2019 - Two-and-a-half years after its release, the US FDA is asking for input from the public on ...
Posted by Michael Wonder on 29 May 2019
FDA officials call for patient-friendly terminology in oncology
29 May 2019 - Officials from the US FDA's oncology offices say they plan to develop a glossary of patient-friendly ...
Posted by Michael Wonder on 07 Mar 2019
Statement from FDA Commissioner on FDA’s steps on naming of biological medicines to balance competition and safety for patients receiving these products
7 March 2019 - We’re at a critical point for the future of biosimilars in the U.S. Millions of American ...
Posted by Michael Wonder on 26 Sep 2018
Mylan and Novartis to FDA: where are the suffixes?
26 September 2018 - Mylan and Novartis are taking issue with the fact that the US FDA has yet to ...
Posted by Michael Wonder on 21 Jun 2018
White House proposes a narrowing of FDA’s mission — and a new name
21 June 2018 - The Trump administration has proposed a fundamental change to the mission of the FDA, one that ...
Posted by Michael Wonder on 19 Nov 2017
FDA begins adding suffixes to newly approved biologics' names
17 November 2017 - The US FDA this week began adding four-letter meaningless suffixes at the end of newly approved ...
Posted by Michael Wonder on 22 Oct 2017
Will the FDA add suffixes to approved biologics' names?
20 October 2017 - Back in January, the US FDA finalised guidance on how biosimilars and their biologic reference products' ...
Posted by Michael Wonder on 13 Jan 2017
FDA finalises guidance on non-proprietary naming of biologics and biosimilars
12 January 2017 - In a departure from the way the WHO and Europe name biologics, the US FDA has ...